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Complement receptor 1-related protein Y (CrrY) is an important cell-surface
regulator of complement that is unique to rodent species. The structure of rat
CrrY domains 1–4 has been determined in two distinct crystal forms and reveals
a7 0   bend between domains 3 and 4. Comparisons of this structure with those of
other complement regulators suggests that rearrangement of this interface may
occur on forming the regulatory complex with C3b.
1. Introduction
Complement constitutes the most ancient arm of the immune system,
providing a ﬁrst line of defence against blood infection by pathogens,
and links innate to cellular immunity (Ricklin et al., 2010). Prevention
of activation on self-surfaces is achieved by complement regulatory
proteins (Liszewski et al., 1996). The two main complement regula-
tion mechanisms that protect self-tissue from unwanted complement
activation are decay-acceleration activity (DAA), in which the
regulator dissociates the complement-activating C3 and C4 conver-
tases, and factor I cofactor activity (CA), in which the regulator
assists the serine protease factor I in cleaving and degrading the same
C3 and C4 convertase precursors, C4b and C3b (Walport, 2001a,b).
Inappropriate or unregulated activation of complement has been
implicated in a wide range of human inﬂammatory conditions
(Szebeni, 2004). In order to investigate these conditions in vivo in
mouse and rat models, the murine complement system and its regu-
lators have been studied and characterized. These studies revealed
that in addition to homologues of the human complement regulators
CD46 (which has CA) and CD55 (which has only DAA), rats and
mice possess an exclusively murine complement regulator: comple-
ment receptor 1-related protein Y (CrrY; Wong & Fearon, 1985;
Foley et al., 1993). CrrY is a membrane-bound protein comprised of
ﬁve complement control protein (CCP) domains [also known as short
consensus repeat (SCR) domains or Sushi domains] in mice and six or
seven CCP domains in rats (owing to alternative splicing), followed
by a transmembrane and cytoplasmic region in both rats and mice.
The protein possesses both DAA and CA (Kim et al., 1995; Li et al.,
1993).
CrrYis expressed across a broad range of tissues both in rats and in
mice, while rat and mouse homologues of the membrane-bound
regulators CD46 and CD55 (which are ubiquitously expressed in
humans) are more tissue-speciﬁc. In mice CD46 is only expressed in
the testis, while in rats expression is restricted to the testis and the
acrosome of developing and mature spermatozoa (Mizuno et al.,
2004). The CD55 homologue in rats is widely expressed, with a tissue
distribution similar to that of human CD55 (Spiller et al., 1999). In
mice, one CD55 homologue encodes a protein with wide tissue
expression, while a second is only expressed in germ cells. Both CA
and DAA are required to maintain homeostasis of the complement
system and given the expression patterns of the CD46 and CD55
homologues CrrY is central to this process (Wu et al., 2008). The
importance of CrrY in controlling complement activation is high-lighted by the embryonic lethal phenotype of CrrY
 /  mice (Xu et al.,
2000).
The ﬁrst four CCP domains of rat CrrY (CrrY1–4) have been shown
to have full complement regulatory activity (Fraser et al., 2002). In
this manuscript, we describe two crystal structures of a construct
consisting of these ﬁrst four CCP domains of rat CrrYand compare it
with its functional human homologues CD55 and CD46.
2. Experimental
2.1. Cloning, expression and purification
A construct spanning the ﬁrst four CCP domains of rat CrrY
(CrrY1–4) was cloned and expressed in Escherichia coli BL21 (DE3)
cells and refolded to allow formation of the eight disulﬁde bonds, as
reported by Fraser et al. (2002). The sample was further puriﬁed
by size-exclusion chromatography on an S200 16/60 column (GE
Healthcare) in Tris-buffered saline (TBS). This material yielded
crystals belonging to space group P21212 (PDB entry 2xrd).
Unfortunately, the initial cloned construct was lost and cloning was
reperformed without signiﬁcant differences in the sequences (the new
construct has one fewer Gly residue at the N-terminus and one extra
Ser residue at the C-terminus). The puriﬁcation protocol was also
optimized to improve the sample purity and the newly cloned and
puriﬁed protein yielded crystals belonging to space group P212121
(PDB entry 2xrb). The novel construct and protein-puriﬁcation
protocol are described in the following.
A cDNA clone of the rat CrrY gene was obtained from the
mammalian gene collection (IMAGE ID 5599318) and a PCR insert
encoding domains 1–4 was produced using the following primers
(Sigma–Aldrich): 50-GCCATCTACTCATATGCAGTGCCCAGC-30
and 50-GCGCTCGAGCTAGGATTTCACCTTGAAGCAGC-30.
This insert was ligated between the NdeI and XhoI sites of a modiﬁed
pET-15b vector (Novagen) that has the NcoI site replaced with an
NdeI site. The sequence was veriﬁed by sequencing.
CrrY1–4 was expressed in E. coli strain B834 (DE3) using Luria–
Bertani broth in the presence of 100 mgm l
 1 ampicillin. Large
cultures were inoculated using a small overnight culture and were
incubated at 310 K with rapid shaking. Protein expression was
induced with 1 mM IPTG when A600 reached 0.6 and the cells were
harvested by centrifugation (20 min, 5000g, 277 K) after 4 h of
induction.
Cells from 4 l growth were resuspended in 40 ml 50 mM Tris, 1 mM
ethylenediaminetetraacetic acid (EDTA), 150 mM NaCl pH 8.0 and
lysed using an Emulsiﬂex C5 High Pressure Homogenizer (Avestin).
20 ml Tween-20 was added to the lysate, which was then rocked at
277 K for 5 min prior to centrifugation (20 min, 39 000g, 277 K). The
supernatant was discarded and the pellet was resuspended in 40 ml
50 mM Tris, 1 mM EDTA, 150 mM NaCl pH 8.0. Again, 20 ml Tween-
20 was added and the sample was rocked at 277 K for 1 h prior to
centrifugation (20 min, 39 000g, 277 K). Inclusion bodies were solu-
bilized in 20 ml 8 M urea, 100 mM Tris, 1 mM EDTA, 25 mM
dithiothreitol (DTT) pH 8.5 and rocked at 277 K for 1 h. The sample
was acidiﬁed to pH 3.5 using HCl and insoluble material was removed
via centrifugation (20 min, 48 000g, 277 K). The supernatant was
dialysed using 10 000 MWCO Snakeskin dialysis tubing (Pierce)
against 6 M urea, 1 mM EDTA pH 3.5 overnight and any precipitate
was removed by centrifugation (20 min, 48 000g, 277 K).
The supernatant was refolded by dropwise addition to 2 l 20 mM
ethanolamine, 1 mM EDTA, 1 mM cysteine, 2 mM cystine at pH 11.0
at 277 K with constant stirring. The protein was then left overnight at
277 K to refold.
The volume of the refolded protein solution was reduced to 50 ml
using a 10 000 MWCO Vivaﬂow concentrator (Sartorius) and the
sample was then dialysed using 10 000 MWCO Snakeskin dialysis
tubing (Pierce) against 25 mM Tris, 10 mM NaCl pH 7.4 overnight at
277 K. The protein was then concentrated to 10 ml in a 10 000
MWCO Vivaspin concentrator (Sartorius) and puriﬁed using an S75
16/60 size-exclusion column (GE Healthcare) equilibrated in 25 mM
Tris, 10 mM NaCl pH 7.4. A ﬁnal puriﬁcation using a Mono Q 5/5 ion-
exchange column (GE Healthcare) was performed using a protocol
that started with binding in 25 mM Tris, 10 mM NaCl pH 7.4 buffer
followed by a gradient reaching 25 mM Tris, 0.3 M NaCl pH 7.4 over
45 column volumes. CrrY1–4 eluted at 9.99 mS cm
 1.
2.2. Crystallization and data processing
Crystals of rat CrrY1–4 grew by vapour diffusion in sitting drops
mixed at room temperature using an Oryx Nano crystallization robot
(Douglas Instruments, UK). P21212 crystals grew in 200 nl drops from
a mixture of the CrrY1–4 protein stock at 6.6 mg ml
 1 with mother
liquor (2 M sodium chloride, 0.1 M sodium acetate pH 4.6) in a 7:3
ratio. Initial poor-quality crystals were optimized by streak-seeding
structural communications
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Table 1
Data-collection and structure-solution statistics.
Values in parentheses are for the last shell.
Structure 2xrb 2xrd
Diffraction source Diamond I04 ESRF ID14-4
Detector ADSC CCD
Temperature (K) 120
Space group P212121 P21212
Z 44
Unit-cell parameters (A ˚ ) a = 21.77, b = 105.34,
c = 152.28
a = 205.48, b = 100.37,
c = 21.95
Resolution (A ˚ ) 29.3–2.5 (2.6–2.5) 38–3.5 (3.7–3.5)
Rmerge 0.12 (0.53) 0.12 (0.45)
hI/(I)i 14.5 (3.8) 5.3 (2.5)
Completeness (%) 99.9 (100.0) 96.9 (94.0)
Multiplicity 6.8 (6.7) 3.0 (2.8)
Data-processing software XDS and SCALA
Phasing method Molecular replacement
Starting search model 1ojv domain 2 and 1gkn domain 15
Alterations to search model CHAINSAW
Solution software Phaser
Table 2
Structure reﬁnement and model validation.
Structure 2xrb 2xrd
Reﬁnement software BUSTER–TNT v.2.9.5
Reﬁnement on F
Resolution (A ˚ ) 29.26–2.50 38–3.5
No. of reﬂections 13030 6390
No. of reﬂections for Rfree 651 (125) 288 (75)
Rwork/Rfree 0.19/0.24 0.25/0.25
No. of atoms
Protein 1966 1933
Ligand/ion 13 ethylene glycol (52 atoms), 3 SO4
2 
(15 atoms), 67 atoms in total
0
Water 125 0
B factors (A ˚ 2)
Protein 31.9 68.2
Ligand/ion 49.8 —
Water 35.1 —
R.m.s. deviations
Bond lengths (A ˚ ) 0.010 0.009
Bond angles ( ) 1.17 1.21
Ramachandran plot analysis
Most favoured regions (%) 96 95
Disallowed regions (%) 0 0and were cryoprotected with 30% glycerol. The P212121 rat CrrY1–4
crystals grew from a 1:1 mixture of CrrY1–4 at 3.3 mg ml
 1 with
mother liquor [0.2 M ammonium sulfate, 0.1 M sodium acetate pH
4.6, 30%(w/v) poly(ethylene)glycol 2000 monomethyl ether (PEG
2000 MME)] in 400 nl drops and were cryoprotected using 15%
ethylene glycol. Diffraction data were collected on beamlines I04 at
the Diamond Light Source (Harwell, England) and ID14-4 at the
ESRF (Grenoble, France) and were processed with XDS (Kabsch,
2010) and SCALA (Evans, 2006) from within the xia2 data-processing
suite (Winter,2010). Data-collection statistics are gathered in Table 1.
2.3. Structure determination and refinement
The structure was initially solved in the lower resolution P21212
form (PDB entry 2xrd) by sequential molecular replacement with the
CCP4 (Winn et al., 2011) program Phaser (McCoy et al., 2007) using
models of homologous individual domains [domain 2 of CD55
(PDB entry 1ok9; Lukacik et al., 2004) and domain 15 of human CR1
(PDB entry 1gkn; Smith et al., 2002)] trimmed using the program
CHAINSAW (Stein, 2008). This model was then used to determine
the structure of the higher resolution P212121 form (PDB entry 2xrb)
by molecular replacement, again using Phaser. The structures were
built and reﬁned iteratively using BUSTER–TNT (Blanc et al., 2004)
and Coot (Emsley et al., 2010), using secondary-structure target
restraints in the lower resolution form (Table 2). Stereo images of a
representative volume of the crystal electron density and of the entire
protein main chain are shown in Fig. 1. The structures were deposited
in the PDB with accession codes 2xrb and 2xrd.
3. Results and discussion
The two crystal structures of rat CrrY1–4 show a hockey-stick-shaped
molecule with the elongated handle comprising CCP domains 1–3,
with approximate dimensions 25   25   120 A ˚ , and the blade made
by CCP domain 4 (Fig. 1a). The electron density of the crystal form
diffracting to 2.5 A ˚ resolution allowed unambiguous tracing of resi-
dues 37–290 (Fig. 1b). The loop 52–54 is poorly ordered in the lower
resolution structure. The domains are standard CCP domains and are
organized in -sheets held together by two disulﬁde bridges (Fig. 2a).
In both crystal forms rat CrrY1–4 retains the same overall confor-
mation and secondary-structure elements, which can be taken to be
representative of its solution structure. Small changes at the CCP1–
CCP2 and CCP3–CCP4 interdomain junctions induced by the
different crystal environments in the two crystal forms cause the two
models to superpose with an overall r.m.s.d. on C
 atoms of 1.3 A ˚
over 239 residues. The structural agreement within the individual
CCP modules is closer, with r.m.s.d.s on C
 atoms of 0.53, 0.12, 0.29
and 0.60 A ˚ for CCP1, CCP2, CCP3 and CCP4, respectively, over the
 60 residues of each CCP domain between the two crystal forms.
The overall arrangement of CrrY1–4 is very similar to those
observed in the crystal structures of other two factor I (fI) cofactors,
structural communications
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Figure 1
Stereographic images of the backbone of the CrrY1–4 structure and of a portion of the CrrY1–4 crystal electron density. (a) shows the backbone of CrrY1–4 coloured in
rainbow colours: blue to red from the N-terminus to the C-terminus. (b) shows a representative sample of the electron density contoured at 1.0 around Phe180. A few
residues are labelled. This ﬁgure was made using PyMOL (DeLano, 2002).fH1–4 (Wu et al., 2009) and CD461–4 (Persson et al., 2010). The fH1–4
cofactor, as seen in the crystal structure of the C3b–fH1–4 complex
(Wu et al., 2009), overlays with CrrY1–4 particularly well in the ﬁrst
three domains, which are predicted to form the bulk of the contacts
with fI (28% sequence identity, r.m.s.d. on C
 atoms of 1.6 A ˚ over 180
residues). Fig. 2(b) shows both our crystal structures of CrrY1–4
overlaid on this structure of fH1–4. Similarly, the ﬁrst three rat CrrY
CCP domains, CrrY1–3, overlay with CD461–3 with an r.m.s.d. on C

atoms of 1.92 A ˚ (34% sequence identity). Fig. 2(c) shows the overlay
of CrrY1–4 with fH1–4 and CD46 in the context of the cofactor–C3b
complex on the basis of alignment of domains 2 and 3. All three
cofactors also share a patch of negatively charged residues on the
surface that could contact factor I (Roversi et al., 2011; see Fig. 3).
The rat CrrY1–4 CCP3–CCP4 interdomain interface, where the
hockey-stick handle meets the blade, buries  300 A ˚ 2 and is centred
on speciﬁc contacts between hydrophobic patches on CCP3 (residues
162–167) and CCP4 (residues 228–234 and 278–279), forming a kink
in the structure. A kink was predicted at this interface by a solution-
scattering study (Aslam et al., 2003). The fH1–4 molecule in the crystal
structure of domains 1–4 of fH (fH1–4) in complex with C3b also
bends between CCP3 and CCP4 and this has been proposed to be
crucial to function (Wu et al., 2009). The structure of CD461–4,
recently determined in complex with a viral receptor also shows a
pronounced bend at the same domain interface (Persson et al., 2010).
Thus, a kink at the interface between domains CCP3 and CCP4 in
CrrY1–4,f H 1–4 and CD461–4 is likely to be a shared feature of all fI
cofactors.
In the central portion of the regulator, the structure of fH2–3
overlays onto CrrY2–3 and CD462–3 with r.m.s.d.s of 1.4 and 1.8 A ˚ 2,
respectively, showing that CCP2 and CCP3 are not likely to change
much upon going from free tobound regulator. The major differences
between the free (CrrY1–4, CD461–4) and C3b-bound (fH1–4) regula-
tors localize at the CCP1–CCP2 and CCP3–CCP4 interfaces, which
appear to be remodelled in forming the regulatory complex, bringing
domains CCP1 and CCP4 closer to C3b. The change in orientation of
CCP4 with respect to CCP2 and CCP3 is particularly striking when
comparing the bound and unbound regulators, with CCP4 rotated
more than 70  away from C3b in both the unbound structures
structural communications
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Figure 2
Factor I cofactors. (a) The crystal structure of the fI cofactor rat CrrY1–4 (PDB entry 2xrb) as a cartoon representation rainbow coloured from the N-terminus (red) to the
C-terminus (blue). (b) Overlay of the crystal structures of CrrY1–4 (PDB entries 2xrb and 2xrd; rainbow coloured) on the structure of fH1–4 from the C3b–fH1–4 binary
complex (PDB entry 2wii; Wu et al., 2009; grey). (c) Overlay of CrrY1–4 (blue, this work) andCD461–4(orange; PDB entry 3o8e; Persson et al., 2010) on the crystal structure of
the complex between fH1–4 and C3b (PDB entry 2wii). This ﬁgure was made using PyMOL (DeLano, 2002).(overlaid as described above) compared with the bound fH. In this
context it is interesting to note that CD55, a regulator that does not
possess cofactor activity, lacks a functional and structural equivalent
of this fourth domain. We propose that the structural rearrangements
at the CCP1–CCP2 and CCP3–CCP4 junctions upon binding to the
C3b, as illustrated in Fig. 4, are key to formation of the cofactor–C3b
regulatory complex.
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Figure 3
Electrostatic potential surfaces for CrrY1–4,f H 1–4 and CD551–4 computed with the
APBS tool (Unni et al., 2011) within the computer program PyMOL (DeLano,
2002). Contour levels:  3 kT/e (red) and +3 kT/e (blue). Shown are fH1–4 from the
crystal structure of its complex with C3b (PDB entry 2wii), CrrY1–4 and CD551–4
(from PDB entry 1ojv). CD55 is placed so that the functionally and structurally
equivalent portion CCP2–CCP4 is aligned with CCP1–CCP3 in fH and CrrY
(Harris et al., 2007; Hocking et al., 2008; Wu et al., 2009). On the surface of the
cofactors (CrrY1–4 and fH1–4) a strongly negatively charged patch is visible that is
much weaker in CD551–4 (which only has decay-accelerating activity).
Figure 4
A cartoon illustrating the conformational rearrangement in the cofactor upon
transition from the free unliganded state to the complex with C3b. The C3b
representation is adapted from Wu et al. (2009). C345c domain, light bronze; CUB
domain, pink; TED domain, light green (with the thioester as a red dot); LNK,
0NT and MG domains of C3b, light grey for CrrY1–4,f H1–4 and CD551–4.T h e
functionally important cofactor CCP1–CCP4 domains are represented as ovals.
Since several of the cofactor contain subsequent CCP domains, a few more have
been sketched in dashed lines.